Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects
- First Posted Date
- 2014-02-12
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 7
- Registration Number
- NCT02060266
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: placebo
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 388
- Registration Number
- NCT02054897
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom
A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2014-01-14
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 41
- Registration Number
- NCT02035371
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Hannover, Germany
Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A
- First Posted Date
- 2014-01-14
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 69
- Registration Number
- NCT02035384
- Locations
- 🇨🇭
Novo Nordisk Investigational Site, Zürich, Switzerland
A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2019-01-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 501
- Registration Number
- NCT02034513
- Locations
- 🇵🇷
Novo Nordisk Investigational Site, Manati, Puerto Rico
A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2014-01-10
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 46
- Registration Number
- NCT02033239
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 721
- Registration Number
- NCT02030600
- Locations
- 🇵🇷
Novo Nordisk Investigational Site, San Juan, Puerto Rico
Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects
Phase 1
Completed
- Conditions
- DiabetesHealthyDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT02022254
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
- First Posted Date
- 2013-12-20
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 56
- Registration Number
- NCT02016911
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Bratislava, Slovakia
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function
- First Posted Date
- 2013-12-18
- Last Posted Date
- 2018-04-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 71
- Registration Number
- NCT02014259
- Locations
- 🇭🇺
Novo Nordisk Investigational Site, Budapest, Hungary
© Copyright 2025. All Rights Reserved by MedPath